MGI Pharma price target cut by Merrill

MGI Pharma Inc. was maintained by Merrill Lynch analyst Eric Ende at a buy rating but the price target was lowered on the stock to $31 per share from $32 on its acquisitions of Guilford Pharmaceuticals Inc. Merrill also reduced its EPS estimates through 2007 due to dilution from the merger, but lifted the 2008 estimate. MGI Pharma shares Friday slipped $0.02, or 0.08%, to $26.08 on volume of 1,161,611 shares versus the three-month running average of 1,323,010 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.